首页> 外文期刊>Journal of hypertension >Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment
【24h】

Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment

机译:抗高血压处理对24小时血压变异性的影响:基于OLMESARTAN单体或组合治疗的动态血压监测研究汇集了个体数据分析

获取原文
获取原文并翻译 | 示例
           

摘要

Objective:To evaluate the impact of olmesartan alone or combined with one to three antihypertensive drugs on 24-h blood pressure variability (BPV) and on distribution of BP reduction in a pooled individual data analysis of 10 double-blind, randomized, ambulatory BP monitoring (ABPM) studies.Methods:ABPMs were performed before and after 6-12 weeks of treatment with placebo (n=119), active control monotherapy [n=1195, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers (DCCBs)] olmesartan monotherapy (n=1410), active control dual combination [n=79, DCCB+thiazide diuretic (TD)], olmesartan dual combination (n=637, DCCB or TD), and triple combination therapy (n=102, DCCB+TD). 24-h BPV was calculated as unweighted or weighted SD of the mean BP, and average real variability. BP control was assessed by smoothness index and treatment-on-variability index.Results:The greatest effect on 24-h systolic BPV/diastolic BPV was observed under olmesartan triple [-2.6/-1.9; -1.9/-1.3; -1.4/-1.3mmHg] and active control dual combination [-1.8/-1.4; -1.9/-1.5; -1.2/-1.1mmHg]. Smoothness indexes and treatment-on-variability indexes were significantly (P=0.0001) higher under olmesartan dual (1.53/1.22, 1.67/1.29, 2.05/1.59), olmesartan triple (2.47/1.85, 2.80/2.06, 3.64/2.67), or active control dual combination (1.70/1.26, 1.85/1.33, 2.29/1.65) than under monotherapies (control: 0.86/0.73, 0.80/0.65, 1.01/0.82; olmesartan: 1.02/0.86, 0.95/0.78, 1.23/1.00). They were also greater in patients receiving high-dose olmesartan monotherapy or high-dose olmesartan dual combination than in the corresponding low-dose group.Conclusion:Olmesartan plus a DCCB and/or a TD produces a larger, more sustained, and smoother BP reduction than placebo and monotherapies, a desirable feature for a more effective prevention of the cardiovascular consequences of uncontrolled hypertension.
机译:目的:评价Olmesartan单独的影响或将一对三种抗高血压药物组合在24小时血压变异性(BPV)和BP汇总数据分析中的分配10双盲,随机,动态BP监测(ABPM)研究。方法:在用安慰剂(n = 119)处理6-12周的治疗前后进行Abpms [n = 1195,血管紧张素II受体阻滞剂(ARBS ),二氢吡啶钙通道阻滞剂(DCCB)] Olmesartan单药治疗(n = 1410),有源控制双组合[n = 79,DCCB +噻嗪类利尿(Td)],Olmesartan双组合(n = 637,DCCB或Td),和三重组合疗法(n = 102,DCCB + Td)。将24-H BPV计算为平均BP的未加权或加权SD,以及平​​均真实变异性。通过平滑度指数和可变异性指数评估BP对照。结果:在Olmesartan Triple [-2.6 / -1.9下,观察到对24-h收缩性BPV /舒张性BPV的最大效果[-2.6 / -1.9; -1.9 / -1.3; -1.4 / -1.3mmhg]和主动控制双组合[-1.8 / -1.4; -1.9 / -1.5; -1.2 / -1.1mmg]。 OLMESARTAN DUAL(1.53 / 1.22,1.67 / 1.29,2.05 / 1.59),OLMESARTAN三重(2.47 / 1.85,2.80 / 2.06,3.64 / 2.67)下平滑度指数显着显着(P = 0.0001)(P = 0.0001)或主动控制双组合(1.70 / 1.26,1.85 / 1.33,2.29 / 1.65)比单一医疗下(控制:0.86 / 0.73,0.80 / 0.65,1.01 / 0.82; Olmesartan:1.02 / 0.86,0.95 / 0.78,1.23 / 1.00) 。在接受高剂量Olmesartan单一疗法或高剂量Olmesartan双组合的患者中也更大的是比在相应的低剂量组中的患者。结论:olmesartan加上DCCB和/或TD产生更大,更持续,更顺畅的BP减少比安慰剂和单疗法,一个理想的特征,更有效地预防不受控制的高血压的心血管后果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号